Acalypha indica is a medicinal plant of Euphorbiaceae family. In present work, metabolomics of Acalypha indica inflorescence extract (AIIE) and its antioxidant potential was studied. HRMS (High resolution mass spectrometry) of AIIE showed the presence of 17 major compounds of pharmaceutical importance. FTIR (Fourier Transform Infrared) analysis showed the presence of characteristic functional groups of different metabolites. Antioxidant potential of the extract was checked by using different solvents and different assays: DPPH (2,2- Diphenyl-1-picrylhydrazyl) scavenging, ABTS (2,2’-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid)) scavenging and Phosphomolybdenum method. Extract prepared in butanol showed maximum antioxidant activity (IC50: 545.13 µg/ml) in DPPH ((2,2- Diphenyl-1-picrylhydrazyl). Butanolic extract also showed maximum antioxidant potential (IC50: 306.04 µmol/AAE/g) in ABTS (2,2’-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) assay. In Phosphomolybdenum method, a concentration dependent increase in antioxidant activity was observed and ethanolic extract showed maximum antioxidant activity (137.12 ± 0.50 mgAAE/g). Butanolic extract showed maximum presence of phenolics (117.08 ± 0.61 mgGAE/g) and flavonoids (79.57 ± 0.22 mgRUE/g). In silico studies of compounds showed 11 compounds following Lipinski’s rule. Bioavailability radar showed Embelin and Ergocalciferol with good oral availability (0.85), Rutin with poor oral availability (0.17) and other compounds with optimum oral availability (0.55). High gastrointestinal absorption was observed for the compounds such as Carvone, Citral, Embelin, Ergocalciferol, Genistein, Isorhamnetin, Luteolin, Mequinol and Quercetin. Compounds showing BBB (blood brain barrier) permeability were Carvone, Citral, Embelin, Ergocalciferol, Mequinol, p-Cymene. No toxicity was observed in Citral. Thus, Acalypha indica inflorescence extract showed significant antioxidant potential, good bioavailability and drug likeness.